Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care
Clinical Questions Addressed by the Comparative Effectiveness Review
The report titled, Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care, addressed the following clinical questions: (1) From an overview of real-world patterns of rFVIIa use and available comparative studies, which clinical populations are receiving off-label rFVIIa and which populations have been scientifically examined, and what are the characteristics of comparative studies evaluating off-label rFVIIa use?; and (2) What are the benefits and harms of using rFVIIa for selected off-label indications in patients with/undergoing: spontaneous intracranial hemorrhage, acquired coagulopathic massive bleeding from body trauma, bleeding from brain trauma, adult cardiac surgery, pediatric cardiac surgery, liver transplantation, or prostatectomy?
Keywords: comparative effectiveness | recombinant factor VIIa | off-label | clinical questions | benefits | harms
- Yank V, Tuohy CV, Logan AC, et al. Comparative Effectiveness of In-Hospital Use of Recombinant Factor VIIa for Off-Label Indications vs. Usual Care, Comparative Effectiveness Review 21 (Prepared by Stanford–UCSF Evidence-based Practice Center under Contract No. 290-02-0017). Rockville, MD: Agency for Healthcare Research and Quality; May 2010. AHRQ Publication No. 10-EHC030-EF.
Your slide tray is being processed.